R 1511

Drug Profile

R 1511

Alternative Names: GK 3; Glucokinase activator (3); R1511

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 16 Apr 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in Europe (PO)
  • 20 Oct 2008 Roche completes a phase I trial in Type-2 diabetes mellitus in Europe
  • 19 Mar 2007 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top